FDA Inspection
Abraxis Bioscience, LLCAbraxis Bioscience, LLC – FDA Inspection, Feb 19, 2020
Record Details
This FDA Inspection record concerns Abraxis Bioscience, LLC, with an inspection on February 19, 2020, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Abraxis Bioscience, LLC
- Inspection Date
- February 19, 2020
- Product Type
- Drugs
View Company Profile
ID · 83c095aa-ddce-4552-a2b5-1812a54e44cd
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1118264
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
4- 21 CFR 211.68(b)Computer control of master formula records
- 21 CFR 211.100(b)Procedure Deviations Recorded and Justified
- 21 CFR 211.100(b)SOPs not followed / documented
- 21 CFR 211.192Written record of investigation incomplete
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Abraxis Bioscience, LLC
9| Date | Classification | Office | Project area |
|---|---|---|---|
| October 6, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 6, 2022 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 17, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 24, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 8, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Abraxis Bioscience, LLC
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.